Table 1.
Clinicopathologic variables of breast cancer patient cohort
| Variables | No. (%) |
|---|---|
| Age (mean ± SD, years) | 54.25 (± 9.77) |
| ≤ 40 years | 165 (8.7%) |
| > 40 years | 1736 (91.3%) |
| ND | 1 (0.1%) |
| Tumour size (mm) | 2.06 ± 1.14 |
| ≤ 20 mm | 1185 (62.3%) |
| > 20 mm | 708 (37.2%) |
| ND | 9 (0.5%) |
| Tumour stage | |
| I | 1203 (63.2%) |
| II | 531 (27.9%) |
| III | 160 (8.4%) |
| ND | 8 (0.4%) |
| Tumour grade | 346 (18.2%) |
| I | |
| II | 632 (33.2%) |
| III | 915 (48.1%) |
| ND | 9 (0.5%) |
| NPI | 4.16 ± 1.18 |
| ≤ 3.4 | 619 (32.5%) |
| 3.41–5.4 | 948 (49.8%) |
| > 5.4 | 324 (17.0%) |
| ND | 11 (0.6%) |
| Lymphovascular invasion | |
| Positive | 492 (25.9%) |
| Negative | 1070 (56.3%) |
| ND | 340 (17.9%) |
| Operation type | |
| Mastectomy | 1067 (56.1%) |
| WLE lumpectomy | 819 (43.1%) |
| ND | 16 (0.8%) |
| ER status | |
| Positive | 1370 (72.0%) |
| Negative | 476 (25.0%) |
| ND | 57 (3.0%) |
| PR status | |
| Positive | 1035 (54.4%) |
| Negative | 739 (38.9%) |
| ND | 128 (6.7%) |
| HER2 status | |
| Positive | 243 (12.8%) |
| Negative | 1602 (84.2%) |
| ND | 57 (3.0%) |
| Basal status | |
| Positive | 368 (19.3%) |
| Negative | 1390 (73.1%) |
| ND | 144 (7.6%) |
| Triple negative status | |
| Positive | 315 (16.6%) |
| Negative | 1516 (79.7%) |
| ND | 71 (3.7%) |
| Breast cancer-specific survival | |
| Alive | 1064 (55.9%) |
| Dead | 505 (26.6%) |
| ND | 333 (17.5%) |
| Recurrence | |
| Present | 752 (39.5%) |
| Not present | 1103 (58.0%) |
| ND | 47 (2.5%) |
| Distant metastasis | |
| Present | 579 (30.4%) |
| Not present | 1310 (68.9%) |
Continuous data are shown as mean ± standard deviation (SD)
NPI Nottingham prognostic value; WLE wide local excision; ER oestrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2; ND not determined